These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 7599447

  • 21. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
    McClung MR, Lippuner K, Brandi ML, Zanchetta JR, Bone HG, Chapurlat R, Hans D, Wang A, Zapalowski C, Libanati C.
    Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386
    [Abstract] [Full Text] [Related]

  • 22. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
    Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, van de Ven CM, Dijkmans BA.
    Osteoporos Int; 2006 Oct; 17(5):716-23. PubMed ID: 16463007
    [Abstract] [Full Text] [Related]

  • 23. Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy.
    Kanaji A, Higashi M, Namisato M, Nishio M, Ando K, Yamada H.
    Lepr Rev; 2006 Jun; 77(2):147-53. PubMed ID: 16895071
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Comparisons of TBS and lumbar spine BMD in the associations with vertebral fractures according to the T-scores: A cross-sectional observation.
    Lee JE, Kim KM, Kim LK, Kim KY, Oh TJ, Moon JH, Choi SH, Lim S, Kim SW, Shin CS, Jang HC.
    Bone; 2017 Dec; 105():269-275. PubMed ID: 28963079
    [Abstract] [Full Text] [Related]

  • 26. Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study.
    Välimäki MJ, Laitinen K, Patronen A, Puolijoki H, Seppänen J, Pylkkänen L, Aranko SM, Sairanen S, Blåfield H, Rekiaro M, Väisänen K, Kormano M, Mäkinen L, Salmi J, Ala-Kaila K, Perttilä J, Vesterinen K, Koivunoro K, Probone Study Group.
    Osteoporos Int; 2002 Dec; 13(12):937-47. PubMed ID: 12459936
    [Abstract] [Full Text] [Related]

  • 27. Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study.
    Boonen S, Lorenc RS, Wenderoth D, Stoner KJ, Eusebio R, Orwoll ES.
    Bone; 2012 Sep; 51(3):383-8. PubMed ID: 22750403
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Treatment of the vertebral crush fracture syndrome with enteric-coated sodium fluoride tablets and calcium supplements.
    Nagant de Deuxchaisnes C, Devogelaer JP, Depresseux G, Malghem J, Maldague B.
    J Bone Miner Res; 1990 Mar; 5 Suppl 1():S5-26. PubMed ID: 2187327
    [Abstract] [Full Text] [Related]

  • 30. Trabecular bone microarchitecture, bone mineral density, and vertebral fractures in male osteoporosis.
    Legrand E, Chappard D, Pascaretti C, Duquenne M, Krebs S, Rohmer V, Basle MF, Audran M.
    J Bone Miner Res; 2000 Jan; 15(1):13-9. PubMed ID: 10646109
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The threshold of bone mineral density for vertebral fracture in female patients with glucocorticoid-induced osteoporosis.
    Kaji H, Yamauchi M, Chihara K, Sugimoto T.
    Endocr J; 2006 Feb; 53(1):27-34. PubMed ID: 16543669
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy.
    Kalder M, Kyvernitakis I, Albert US, Baier-Ebert M, Hadji P.
    Osteoporos Int; 2015 Jan; 26(1):353-60. PubMed ID: 25381047
    [Abstract] [Full Text] [Related]

  • 35. Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis?
    Lems WF, Jacobs JW, Bijlsma JW, van Veen GJ, Houben HH, Haanen HC, Gerrits MI, van Rijn HJ.
    Ann Rheum Dis; 1997 Jun; 56(6):357-63. PubMed ID: 9227164
    [Abstract] [Full Text] [Related]

  • 36. Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis.
    Iwamoto J, Takeda T, Ichimura S, Matsu K, Uzawa M.
    J Orthop Sci; 2003 Jun; 8(4):532-7. PubMed ID: 12898306
    [Abstract] [Full Text] [Related]

  • 37. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis.
    Devogelaer JP, Broll H, Correa-Rotter R, Cumming DC, De Deuxchaisnes CN, Geusens P, Hosking D, Jaeger P, Kaufman JM, Leite M, Leon J, Liberman U, Menkes CJ, Meunier PJ, Reid I, Rodriguez J, Romanowicz A, Seeman E, Vermeulen A, Hirsch LJ, Lombardi A, Plezia K, Santora AC, Yates AJ, Yuan W.
    Bone; 1996 Feb; 18(2):141-50. PubMed ID: 8833208
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Reappraisal of Katsuragi calcium study, a prospective, double-blind, placebo-controlled study of the effect of active absorbable algal calcium (AAACa) on vertebral deformity and fracture.
    Fujita T, Ohue M, Fujii Y, Miyauchi A, Takagi Y.
    J Bone Miner Metab; 2004 Feb; 22(1):32-8. PubMed ID: 14691684
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.